Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors

NCT03164603 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT03164603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2017
Completion date
September 25, 2019
Enrollment
26 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor